School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China.
School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, PR China; School of Public Health, Shaanxi University of Chinese Medicine, Xi'an 712046, PR China.
Free Radic Biol Med. 2024 Oct;223:306-324. doi: 10.1016/j.freeradbiomed.2024.07.036. Epub 2024 Aug 10.
The systemic inflammatory response syndrome (SIRS) represents a self-amplifying cascade of inflammatory reactions and pathophysiological states triggered by infectious or non-infectious factors. The identification of disease targets and differential proteins in the liver (the unique and important immune organ) of SIRS mice treated with the lead compound D1 was conducted using the Genecards database and proteomic analysis, respectively. Subsequently, NOTCH1 was identified as the potential hub target via an intersection analysis between the aforementioned differentially expressed proteins and disease targets. Based on our previous research on the structure-activity relationship, we designed and synthesized a series of SIRS-related derivatives, wherein butyl, halogen, and ester groups were incorporated into benzophenone, aiming at exploring the anti-inflammatory protective action from the perspective of macrophage polarization. Notably, these derivatives exhibited a direct binding capability to the O-glucosylation site (SER496) or its vicinities (such as SER492, VAL485) of NOTCH1 using docking, SPR, DARTS, and CETSA techniques. Mechanistically, derivative D6 exerted anti-inflammatory effects via the dual NOTCH pathway. Firstly, it could inhibit NOTCH1 nuclear transcriptional activity, attenuate the interaction between NICD and RBPJK, concurrently suppress NF-κB and NLRP3 inflammasome (NLRP3, ASC, and cleaved CASP1) activation, and promote NICD (NOTCH1 active fragments) ubiquitination metabolism (the nuclear transcriptional pathway). Secondly, it might possess the ability to increase PGC1α level, subsequently, enhance ATP and MMP levels, mitigate ROS production, increase mitochondrial numbers, and ameliorate mitochondrial inflammatory damage (the mitochondrial pathway). Importantly, the activator Jagged1 could effectively reverse the aforementioned effects, while the inhibitor DAPT exhibited a synergistic effect, suggesting that the nuclear transcriptional regulation and mitochondrial regulation were both in a NOTCH1-dependent manner. Subsequently, it effectively alleviated the inflammatory response and preserved organ function as evidenced by up-regulating M2-type macrophage-related anti-inflammatory cytokines (IL10, TGFβ, CD206, and ARG1) and down-regulating M1-type macrophage-related pro-inflammatory cytokines (NO, IL6, IL18, iNOS, TNFα, CD86, and IL1β). In a word, derivative D6 modulated macrophage polarization and effectively mitigated SIRS by targeting inhibition of the dual NOTCH pathway.
全身炎症反应综合征(SIRS)代表了由感染或非感染因素触发的炎症反应和病理生理状态的自我放大级联。使用 Genecards 数据库和蛋白质组学分析分别对用先导化合物 D1 处理的 SIRS 小鼠肝脏(独特且重要的免疫器官)中的疾病靶点和差异蛋白进行鉴定。随后,通过对上述差异表达蛋白和疾病靶点的交集分析,确定 NOTCH1 为潜在的关键靶点。基于我们之前关于结构-活性关系的研究,我们设计并合成了一系列与 SIRS 相关的衍生物,其中将丁基、卤素和酯基引入二苯甲酮中,旨在从巨噬细胞极化的角度探索抗炎保护作用。值得注意的是,这些衍生物通过对接、SPR、DARTS 和 CETSA 技术,具有与 NOTCH1 的 O-糖基化位点(SER496)或其附近(如 SER492、VAL485)直接结合的能力。在机制上,衍生物 D6 通过双重 NOTCH 途径发挥抗炎作用。首先,它可以抑制 NOTCH1 核转录活性,减弱 NICD 与 RBPJK 的相互作用,同时抑制 NF-κB 和 NLRP3 炎症小体(NLRP3、ASC 和 cleaved CASP1)的激活,并促进 NICD(NOTCH1 活性片段)泛素化代谢(核转录途径)。其次,它可能具有增加 PGC1α 水平的能力,随后增强 ATP 和 MMP 水平,减轻 ROS 产生,增加线粒体数量,并改善线粒体炎症损伤(线粒体途径)。重要的是,激活剂 Jagged1 可以有效逆转上述作用,而抑制剂 DAPT 则表现出协同作用,表明核转录调控和线粒体调控均依赖于 NOTCH1。随后,它通过上调 M2 型巨噬细胞相关抗炎细胞因子(IL10、TGFβ、CD206 和 ARG1)和下调 M1 型巨噬细胞相关促炎细胞因子(NO、IL6、IL18、iNOS、TNFα、CD86 和 IL1β),有效缓解了炎症反应并保护了器官功能。总之,衍生物 D6 通过靶向抑制双重 NOTCH 途径调节巨噬细胞极化,有效缓解 SIRS。